Grade ≥3 all-cause AEs occurred in 27.3% of patients in the ≤200 mg/cycle cohorts and 72.4% in the ≥400 mg/cycle cohorts; the most common were dyspnoea (9.1%) in the former and neutropenia (37.9%) and decreased neutrophil count (24.1%) in the latter, indicating the need for G-CSF at higher doses. This evidence concerns the gene CSF3 and neutropenia.